(Q38753877)

6 September 2017

title

Novel Oral Therapies for Psoriasis and Psoriatic Arthritis (English)

1 reference

6 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26923915%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Richard B Warren

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26923915%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

publication date

29 February 2016

1 reference

American Journal of Clinical Dermatology

6 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26923915%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26923915%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26923915%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

191-200

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26923915%20AND%20SRC:MED&resulttype=core&format=json

Methotrexate for psoriasis in the era of biological therapy.

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Pathogenesis and clinical features of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Interleukin 17-A inhibition in the treatment of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Ponesimod--a future oral therapy for psoriasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Recent developments in adenosine receptor ligands and their potential as novel drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

Sphingosine-1-Phosphate/Sphingosine Kinase Pathway Is Involved in Mouse Airway Hyperresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-016-0179-3

10.1007/S40257-016-0179-3

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26923915%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

31 May 2020

1001316620

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26923915%20AND%20SRC:MED&resulttype=core&format=json